Company

Astellas Pharma, Inc.

Headquarters: Tokyo, Japan

Employees: 15,455

CEO: Mr. Kenji Yasukawa Ph.D.

JPX: 4503 +1.65%

Market Cap

¥3.193 Trillion

JPY as of Jan. 1, 2024

US$22.67 Billion

Market Cap History

Astellas Pharma, Inc. market capitalization over time

Evolution of Astellas Pharma, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Astellas Pharma, Inc.

Detailed Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Top 1-year algo backtest: +313.24%

$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Astellas Pharma, Inc. has the following listings and related stock indices.


Stock: JPX: 4503 wb_incandescent

Stock: FSX: YPH wb_incandescent

Stock: FSX: YPHA wb_incandescent

Stock: OTC: ALPMF wb_incandescent

Stock: OTC: ALPMY wb_incandescent

Details

Headquarters:

2-5-1, Nihonbashi-Honcho

Chuo-Ku

Tokyo, 103-8411

Japan

Phone: 81 3 3244 3000